Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 19-20/2015

01.10.2015 | review

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement

verfasst von: Prof. Dr. Edgar Petru, Christian F. Singer, MD, Stephan Polterauer, MD, Arik Galid, MD, Christian Schauer, MD, Johann Klocker, MD, Michael Seifert, MD, Alexander Reinthaller, MD, Christoph Benedicic, MD, Michael Hubalek, MD, Lukas Hefler, MD, Christian Marth, MD, Tonja Scholl-Firon, MD, Gerhard Bogner, MD, Alain-Gustave Zeimet, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 19-20/2015

Einloggen, um Zugang zu erhalten

Summary

We reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or severe neutropenia after administration of long-acting G-CSF in the same cycle. One study has shown a moderate effect on febrile neutropenia of ciprofloxacin when co-administered with pegfilgrastim. There is broad evidence from meta-analyses that pegfilgrastim effectively reduces severe neutropenia. In parallel, its adverse effects have been studied extensively. All-cause mortality was significantly reduced by pegfilgrastim. The glycopegylated long-acting G-CSF, lipegfilgrastim has demonstrated antineutropenic efficacy similar to that of pegfilgrastimin in one breast cancer study. In another pivitol non-small cell lung cancer study, impaired survival was observed in the lipegfilgrastim group during the first 30 days of study. The European Medicines Agency claimed more profound safety data to be provided for lipegfilgrastim by 2017.
Literatur
1.
Zurück zum Zitat Aapro MS, Bohlius J, Cameron D, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMed Aapro MS, Bohlius J, Cameron D, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMed
2.
Zurück zum Zitat Crawford J, Caserta C, Roila F. Haematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21 (Suppl 5) v246–51. Crawford J, Caserta C, Roila F. Haematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21 (Suppl 5) v246–51.
3.
Zurück zum Zitat Von Minckwitz G, Kümmel S, DuBois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–8.CrossRef Von Minckwitz G, Kümmel S, DuBois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–8.CrossRef
4.
Zurück zum Zitat Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22(13):2587–93.CrossRefPubMed Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22(13):2587–93.CrossRefPubMed
5.
Zurück zum Zitat Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–212.CrossRefPubMed Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–212.CrossRefPubMed
6.
Zurück zum Zitat Timmer-Bonte J, Adang E, Smit H, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–7.CrossRefPubMed Timmer-Bonte J, Adang E, Smit H, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–7.CrossRefPubMed
8.
Zurück zum Zitat De Naurois J, Novitzky-Basso I, Gill M, Marti Marti F, Cullen M, Rolla F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010; 21 (Suppl 5) v252–6.CrossRefPubMed De Naurois J, Novitzky-Basso I, Gill M, Marti Marti F, Cullen M, Rolla F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010; 21 (Suppl 5) v252–6.CrossRefPubMed
9.
Zurück zum Zitat Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.CrossRefPubMed Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.CrossRefPubMed
10.
Zurück zum Zitat NCCN clinical practice guidelines in oncology. Myeloid growth factors. Version 2.2014. NCCN clinical practice guidelines in oncology. Myeloid growth factors. Version 2.2014.
11.
Zurück zum Zitat Crawford J, Allen J, Armitage J, Balducci L, Becker P, Blayney D, Cataland S, Heaney M, Hudock S, Kloth D, Kuter D, Lyman G, McMahon B. Myeloid Growth Factors. JNCCN. 2011;9:1266–90. Crawford J, Allen J, Armitage J, Balducci L, Becker P, Blayney D, Cataland S, Heaney M, Hudock S, Kloth D, Kuter D, Lyman G, McMahon B. Myeloid Growth Factors. JNCCN. 2011;9:1266–90.
12.
Zurück zum Zitat Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the european organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol. 2002;20:3114–21.CrossRefPubMed Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the european organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol. 2002;20:3114–21.CrossRefPubMed
13.
Zurück zum Zitat Hensley M, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresesctable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.CrossRefPubMed Hensley M, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresesctable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.CrossRefPubMed
14.
Zurück zum Zitat Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.CrossRefPubMed Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.CrossRefPubMed
15.
Zurück zum Zitat Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr. 2012;124:412–8.CrossRefPubMed Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr. 2012;124:412–8.CrossRefPubMed
16.
Zurück zum Zitat Citron ML, Berry D, Cirrincione, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukaemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.CrossRefPubMed Citron ML, Berry D, Cirrincione, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukaemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.CrossRefPubMed
17.
Zurück zum Zitat Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.CrossRefPubMed Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.CrossRefPubMed
18.
Zurück zum Zitat Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.CrossRefPubMed Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.CrossRefPubMed
19.
Zurück zum Zitat Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–9.CrossRefPubMed Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–9.CrossRefPubMed
20.
Zurück zum Zitat Bondarenko I, Gladkov O, Elaesser R, Buchner A, Bias P. Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. J Clin Oncol. 2012;30 (Suppl Abstr e19587). Bondarenko I, Gladkov O, Elaesser R, Buchner A, Bias P. Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. J Clin Oncol. 2012;30 (Suppl Abstr e19587).
21.
Zurück zum Zitat Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Avisar N, Bias P, Mueller U. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. International MASCC/ISOO Symposium, 2012;20 (pp S235–S236). Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Avisar N, Bias P, Mueller U. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. International MASCC/ISOO Symposium, 2012;20 (pp S235–S236).
22.
Zurück zum Zitat Lyman G, Dale D, Wolff D, Culakova E, Poniewierski MS, Kuderer NM, Crawford J. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010a;28:2914–24.CrossRefPubMed Lyman G, Dale D, Wolff D, Culakova E, Poniewierski MS, Kuderer NM, Crawford J. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010a;28:2914–24.CrossRefPubMed
23.
Zurück zum Zitat Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010b;116:5555–63.CrossRefPubMed Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010b;116:5555–63.CrossRefPubMed
24.
Zurück zum Zitat Lyman GH. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol. 2003;30(4 Suppl 13):10–7.CrossRefPubMed Lyman GH. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol. 2003;30(4 Suppl 13):10–7.CrossRefPubMed
25.
Zurück zum Zitat Sierra J, Harms R, Mo M, Vogel C. Evaluation of reported bone pain in patients receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol. 2009;27:15S (Suppl; Abstr 9621). Sierra J, Harms R, Mo M, Vogel C. Evaluation of reported bone pain in patients receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol. 2009;27:15S (Suppl; Abstr 9621).
26.
Zurück zum Zitat Kubista E, Glaspy J, Holmes F, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3:391–8.CrossRefPubMed Kubista E, Glaspy J, Holmes F, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3:391–8.CrossRefPubMed
27.
Zurück zum Zitat Schwartzberg L, Mo M, Harms R, Vogel C. Reported bone pain in patients with breast cancer receiving taxane-based chemotherapy in clinical trials of pegfilgrastim. Cancer Res. 2009;69:(Suppl 24) (Abstr 1117). Schwartzberg L, Mo M, Harms R, Vogel C. Reported bone pain in patients with breast cancer receiving taxane-based chemotherapy in clinical trials of pegfilgrastim. Cancer Res. 2009;69:(Suppl 24) (Abstr 1117).
28.
Zurück zum Zitat Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opinion. 2007;23:2283–95.CrossRef Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opinion. 2007;23:2283–95.CrossRef
29.
Zurück zum Zitat Kirshner J, Heckler E, Dakhil S, et al. Prevention of pegfilgrastim-induced bone pain: A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients. J Clin Oncol. 2010;28. (Suppl 639 s Abstr 9014). Kirshner J, Heckler E, Dakhil S, et al. Prevention of pegfilgrastim-induced bone pain: A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients. J Clin Oncol. 2010;28. (Suppl 639 s Abstr 9014).
30.
Zurück zum Zitat Fachinformation Neulasta® August 2014. Fachinformation Neulasta® August 2014.
31.
Zurück zum Zitat Leitgeb C. Quality of life and cytokines in oncological therapy. Wien Med Wochenschr. 1998;148:424–6.PubMed Leitgeb C. Quality of life and cytokines in oncological therapy. Wien Med Wochenschr. 1998;148:424–6.PubMed
32.
Zurück zum Zitat Cooper K, Madan J, Whyte S, Stevenson M, Akehurst R. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.PubMedCentralCrossRefPubMed Cooper K, Madan J, Whyte S, Stevenson M, Akehurst R. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.CrossRefPubMed Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.CrossRefPubMed
34.
Zurück zum Zitat Gregory S, Schwartzberg L, Mo M, Sierra J, Vogel C. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncol. 2010;7:297–306.CrossRef Gregory S, Schwartzberg L, Mo M, Sierra J, Vogel C. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncol. 2010;7:297–306.CrossRef
35.
Zurück zum Zitat Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–24.CrossRefPubMed Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–24.CrossRefPubMed
36.
Zurück zum Zitat European Medicines Agency. Assessment report Lonquex. Procedure No. EMEA/H/C/002556/0000. European Medicines Agency. Assessment report Lonquex. Procedure No. EMEA/H/C/002556/0000.
37.
Zurück zum Zitat De Boer RH, Patterson WK, Beith J, Lynch J, Selva S, Rocchi L, Beer F, Lewis CR. Eur J Cancer. 2008;6:128(Suppl Abstr 269).CrossRef De Boer RH, Patterson WK, Beith J, Lynch J, Selva S, Rocchi L, Beer F, Lewis CR. Eur J Cancer. 2008;6:128(Suppl Abstr 269).CrossRef
38.
Zurück zum Zitat Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6:133–40.PubMedCentralCrossRefPubMed Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6:133–40.PubMedCentralCrossRefPubMed
39.
Zurück zum Zitat Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–7.CrossRefPubMed Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–7.CrossRefPubMed
40.
Zurück zum Zitat Mattioli R, Gridelli C, Castellanos J, Duque A, Falcone A, Mansutti M, Bacon P, Lawrinson S, Skacel T, Casas A. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clin Transl Oncol. 2009;11:842–8.CrossRefPubMed Mattioli R, Gridelli C, Castellanos J, Duque A, Falcone A, Mansutti M, Bacon P, Lawrinson S, Skacel T, Casas A. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clin Transl Oncol. 2009;11:842–8.CrossRefPubMed
41.
Zurück zum Zitat Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007;12:484–94.CrossRefPubMed Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007;12:484–94.CrossRefPubMed
42.
Zurück zum Zitat Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M, Schütte M, Easton V, Skacel T, Bacon P, Brugger W. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol. 2007;64:64–72.CrossRefPubMed Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M, Schütte M, Easton V, Skacel T, Bacon P, Brugger W. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol. 2007;64:64–72.CrossRefPubMed
43.
Zurück zum Zitat Buchner A, Bias P, Kaufmann M. A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. J Clin Oncol. 2011;29 (Suppl Abstr 9080). Buchner A, Bias P, Kaufmann M. A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. J Clin Oncol. 2011;29 (Suppl Abstr 9080).
44.
Zurück zum Zitat Johnston E, Crawford J, Blackwell, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–8.PubMed Johnston E, Crawford J, Blackwell, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–8.PubMed
45.
Zurück zum Zitat Smith F. Neutropenia and anxiety in advance non-small cell lung cancer patients: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications. J Clin Oncol 2005;23 (Suppl Abstr 8173). Smith F. Neutropenia and anxiety in advance non-small cell lung cancer patients: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications. J Clin Oncol 2005;23 (Suppl Abstr 8173).
46.
Zurück zum Zitat Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N, Pettengell R. Pegfilgrastim for peripheral CD34 + mobilization in patients with solid tumours. Bone Marrow Transplant. 2009;43:927–34.CrossRefPubMed Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N, Pettengell R. Pegfilgrastim for peripheral CD34 + mobilization in patients with solid tumours. Bone Marrow Transplant. 2009;43:927–34.CrossRefPubMed
47.
Zurück zum Zitat Gladkov O, Bondarenko I, Elsaesser R, Buchner A, Bias P. Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Ann Oncol. 23 (Suppl 9) ix500. (Abstr. 1548PD). Gladkov O, Bondarenko I, Elsaesser R, Buchner A, Bias P. Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Ann Oncol. 23 (Suppl 9) ix500. (Abstr. 1548PD).
48.
Zurück zum Zitat Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.PubMed Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.PubMed
49.
Zurück zum Zitat George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1691–6.CrossRefPubMed George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1691–6.CrossRefPubMed
50.
Zurück zum Zitat Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J. Hiddemann W, International Study Group. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1503–8.CrossRefPubMed Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J. Hiddemann W, International Study Group. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:1503–8.CrossRefPubMed
51.
Zurück zum Zitat Lopez A. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: arandomised phase II study. Blood. 2004;104:904A–5A.CrossRef Lopez A. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: arandomised phase II study. Blood. 2004;104:904A–5A.CrossRef
52.
Zurück zum Zitat Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 2008;93:405–12.CrossRefPubMed Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 2008;93:405–12.CrossRefPubMed
53.
Zurück zum Zitat Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21:514–9.CrossRefPubMed Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21:514–9.CrossRefPubMed
54.
Zurück zum Zitat Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer A, Herrmann R, Arthur C, Durrant S, van Kerkhoven M, MacMillan J, Mrongovius R. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47:2344–50.CrossRefPubMed Wolf M, Bentley M, Marlton P, Horvath N, Lewis ID, Spencer A, Herrmann R, Arthur C, Durrant S, van Kerkhoven M, MacMillan J, Mrongovius R. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47:2344–50.CrossRefPubMed
55.
Zurück zum Zitat Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9:95–101.CrossRefPubMed Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9:95–101.CrossRefPubMed
56.
Zurück zum Zitat Pirker R, Ulsperger E, Messner J, Aigner K, Forstner B, Bacon P, Easton V, Skacel T. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung. 2006;184:279–85.CrossRefPubMed Pirker R, Ulsperger E, Messner J, Aigner K, Forstner B, Bacon P, Easton V, Skacel T. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung. 2006;184:279–85.CrossRefPubMed
57.
Zurück zum Zitat Engert A, Bredenfeld H, Döhner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica. 2006;91:546–9.PubMed Engert A, Bredenfeld H, Döhner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica. 2006;91:546–9.PubMed
58.
Zurück zum Zitat Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 2008;8:195.PubMedCentralCrossRefPubMed Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 2008;8:195.PubMedCentralCrossRefPubMed
59.
Zurück zum Zitat Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137–43.CrossRefPubMed Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137–43.CrossRefPubMed
60.
Zurück zum Zitat Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010;28(8):1329–36.PubMedCentralCrossRefPubMed Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010;28(8):1329–36.PubMedCentralCrossRefPubMed
Metadaten
Titel
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement
verfasst von
Prof. Dr. Edgar Petru
Christian F. Singer, MD
Stephan Polterauer, MD
Arik Galid, MD
Christian Schauer, MD
Johann Klocker, MD
Michael Seifert, MD
Alexander Reinthaller, MD
Christoph Benedicic, MD
Michael Hubalek, MD
Lukas Hefler, MD
Christian Marth, MD
Tonja Scholl-Firon, MD
Gerhard Bogner, MD
Alain-Gustave Zeimet, MD
Publikationsdatum
01.10.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 19-20/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0392-3

Weitere Artikel der Ausgabe 19-20/2015

Wiener Medizinische Wochenschrift 19-20/2015 Zur Ausgabe